Publications by authors named "Martin Simkovic"

Claim this Profile
C
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL.
Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel, Christina Papangelou, Evangelia Minga, Martin Simkovic

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, Paolo Ghia, Ian W Flinn

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Jennifer R Brown, John F Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach

N Engl J Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, Constantine S Tam

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.
Laura Ondrisova, Vaclav Seda, Krystof Hlavac, Petra Pavelkova, Eva Hoferkova, Martin Simkovic

J Clin Invest· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
Thomas Chatzikonstantinou, Lydia Scarfò, Eva Minga, Georgios Karakatsoulis, Dimitra Chamou, Martin Simkovic

Hemasphere· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič

Cancer Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Martin Simkovic

Future Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Antimicrobial Effects of Myrosinase Hydrolysis Products Derived from Glucosinolates Isolated from .
Zoltán Polozsányi, Helena Galádová, Michal Kaliňák, Martin Jopčík, Barbora Kaliňáková

Plants (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis, Christos Demosthenous

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Martin Simkovic

Lancet Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL.
Constantine Tam, Javier Pinilla-Ibarz, Carolina G Castillo, Ana Cristina Fenili, Kathryn Huntley

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Thomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Martin Simkovic

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Martin Špaček, Lukáš Smolej, Martin Šimkovič, Lucie Nekvindová, Zlatuše Křístková

Br J Haematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Martin Simkovic

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Martin Šimkovič, Peter Turcsányi, Martin Špaček, Jana Mihályová, Pavlína Ryznerová

Ann Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič

Cancer Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Martin Simkovic

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysak, Martin Šimkovič

Hemasphere· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum.
Dominika Écsiová, Martin Šimkovič, Martin Uher, Miloš Hroch

J Pharm Biomed Anal· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Sulforaphane-Induced Cell Death upon Repeated Passage of Either P-Glycoprotein-Negative or P-Glycoprotein-Positive L1210 Cell Variants.
Anna Bertova, Szilvia Kontar, Zoltan Polozsanyi, Martin Simkovic, Zuzana Rosenbergova

Int J Mol Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic

J Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis